Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 29, 2026
Why Is Parsons Corporation (PSN) Stock Down -40.35% Today?

Why Is Parsons Corporation (PSN) Stock Down -40.35% Today?

Key Takeaways

  • Parsons Corporation shares plummeted approximately 40.35% in Wednesday's trading session, collapsing from a prior close of $62.03 to roughly $37.00 in early trading.
  • The primary catalyst was a disastrous Q2 2026 earnings report featuring a surprise adjusted loss of $0.06 per share versus analyst expectations of a $0.76 profit, alongside $118 million in portfolio-shaping and joint-venture charges.
  • Full-year guidance was slashed across the board, with revenue now seen at $6.2 billion to $6.5 billion, down from the prior range of $6.5 billion to $6.8 billion and well below the $6.66 billion consensus.
  • Operating income collapsed 99% to just $1 million, while GAAP net income swung to a $15 million loss from a $55 million profit in the same quarter last year.
  • The selloff pushed shares decisively below the previous 52-week low of $46.88, marking the stock's lowest level in years and triggering a fundamental reassessment of the company's near-term earnings trajectory.
  • Traders now await management's conference call commentary and potential analyst downgrades as the market digests the magnitude of the operational reset.

Opening Summary

PSN, Parsons Corporation — a Virginia-based technology-driven provider of engineering, cybersecurity, and mission-critical solutions for the U.S. defense, intelligence, and global infrastructure markets — suffered one of its worst single-day declines in history on Wednesday. Shares cratered roughly 40.35%, tumbling from Tuesday's closing price of $62.03 to approximately $37.00 in early trading on July 29, 2026. The rout was triggered by a deeply disappointing second-quarter earnings release that revealed massive contract-related charges, a surprise adjusted loss, and a sharply reduced full-year outlook that caught Wall Street by surprise.

Earnings Miss: A Quarter Defined by Charges

Parsons reported Q2 2026 revenue of $1.58 billion, missing the analyst consensus of $1.61 billion and essentially flat compared to the prior-year period. But the revenue shortfall was the least of investors' concerns. The company posted an adjusted loss of $0.06 per share — a staggering 92% below the $0.76 profit that analysts had forecast. On a GAAP basis, the picture was even bleaker: net income swung to a loss of $15 million, or negative $0.14 per diluted share, compared to a $55 million profit ($0.50 per share) in Q2 2025. Operating income evaporated, plunging 99% year-over-year to just $1 million.

The headline numbers were overwhelmed by $118 million in non-recurring charges, including a $77.5 million pre-tax loss on two Federal Solutions contracts held for sale and a $40.9 million pre-tax charge tied to a Critical Infrastructure joint venture program that was hit by historic rainfall — described as the highest in over a century — and resulting project delays. Management characterized these as one-time, portfolio-shaping actions designed to exit underperforming or high-risk contracts and reposition the business toward higher-margin, sustainable growth.

Guidance Slashed, Confidence Shaken

Compounding the earnings shock, Parsons delivered a sweeping guidance cut that further rattled investor confidence. Full-year 2026 revenue guidance was reduced to a range of $6.2 billion to $6.5 billion, down from the prior forecast of $6.5 billion to $6.8 billion and meaningfully below the $6.66 billion Wall Street consensus. Adjusted EBITDA guidance was trimmed to $500 million to $560 million, compared with the earlier range of $615 million to $675 million and well under the $653 million analysts had been modeling. Operating cash flow guidance was also lowered, to $430 million to $490 million.

The guidance reset reflects both the direct impact of portfolio exits and a more cautious outlook on certain federal programs. With the company already trading 44% below its 52-week high of $89.50 before Wednesday's report — a reflection of multiple revenue misses over the prior two years — the fresh cut deepened concerns that Parsons is facing structural headwinds in converting its backlog into consistent, profitable growth.

Bright Spots Buried Under the Rubble

Stripping out the charges, Parsons' core business showed genuine resilience. Normalized adjusted EBITDA rose 8% year-over-year to $161 million, with margins expanding 70 basis points to 10.1%. The Critical Infrastructure segment, excluding the joint venture charge, posted an 18% increase in adjusted EBITDA to $97 million and an 11.9% margin. Contract awards surged 24% to $1.9 billion, producing a quarterly book-to-bill ratio of 1.2x, and total backlog grew to $9.3 billion — 71% of which is funded. The Middle East business delivered 10% organic revenue growth and a 1.1x book-to-bill ratio despite ongoing regional conflict. Key wins included a $514 million Missile Defense Agency extension and $400 million in defense and intelligence Other Transaction Agreements.

Yet these positives were entirely overshadowed by the scale of the charges and the guidance downgrade. The market's verdict was swift and unequivocal: the operational reset, however strategically justified, represents a far more painful near-term adjustment than investors had priced in.

Market Context and Trading Activity

Volume in PSN shares was dramatically elevated, running many multiples above the stock's average daily volume of approximately 1.17 million shares as panic selling gripped the name. The move ran sharply counter to the broader market, with the S&P 500 and Nasdaq trading roughly flat to slightly positive on the day. The decline also stood in stark contrast to the performance of defense-sector peers: RTX and LMT both posted strong quarterly results with year-over-year revenue growth of 14.5% and 10.5%, respectively, underscoring that Parsons' troubles were company-specific rather than sector-wide. The stock crashed through its prior 52-week low of $46.88 within minutes of the open, wiping out any nearby technical support and leaving shares at levels not seen in several years.

What Comes Next for PSN

The immediate focus turns to management's conference call commentary, where CEO Carey Smith and CFO Matt Ofilos will face pointed questions about the timeline for closing the divestitures, the outlook for the remaining portfolio, and whether further charges could materialize. Analysts are widely expected to issue downgrades and price-target cuts in the coming days, with nine of thirteen firms having carried "Buy" ratings heading into the print. For investors, the key question is whether the portfolio-shaping strategy — exiting good work to win better work, as management has framed it — can ultimately deliver the margin expansion and earnings consistency the market demands. The $9.3 billion backlog and $55 billion pipeline provide a foundation, but execution risks remain elevated, leverage is rising, and free cash flow came in at effectively zero for the quarter. The stock's path to recovery will depend on clean execution in the second half of 2026 and evidence that the worst of the contract-related fallout is now behind the company.

Trending AI Robots

In volatile market environments like the one surrounding PSN today, traders increasingly turn to automated strategies for disciplined, data-driven decision-making. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions, drawn from a library of hundreds of bots covering thousands of tickers across multiple strategies and timeframes. Each bot is designed with distinct performance metrics, trading styles, and symbol coverage — from swing trading to trend following — allowing users to identify approaches aligned with their own objectives and risk tolerance. Explore which AI strategies are leading the market right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PSN

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PSN in -1.51% downward trend, sliding for three consecutive days on September 30, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PSN declined for three days, in 174 of 288 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PSN as a result. In 46 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.

The Moving Average Convergence Divergence Histogram (MACD) for PSN turned negative on September 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 19 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

The Aroon Indicator for PSN entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PSN's RSI Oscillator exited the oversold zone, 21 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where PSN advanced for three days, in 220 of 333 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

PSN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.689) is normal, around the industry mean (7.462). P/E Ratio (28.690) is within average values for comparable stocks, (67.645). Projected Growth (PEG Ratio) (7.580) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.801) is also within normal values, averaging (141.758).

The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 8.39B. The market cap for tickers in the group ranges from 100 to 207.9B. IBM holds the highest valuation in this group at 207.9B. The lowest valued company is ARSC at 100.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -0%. VEEA experienced the highest price growth at 100%, while SGRX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was 40%. For the same stocks of the Industry, the average monthly volume growth was 43% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 64
Price Growth Rating: 60
SMR Rating: 73
Profit Risk Rating: 93
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
PSN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of technical design, engineering and software services

Industry InformationTechnologyServices

Industry
Information Technology Services
Address
14291 Park Meadow Drive
Phone
+1 703 988-8500
Employees
10600
Web
https://www.parsons.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.